Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get...
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that...
